Delivery that Restores
Immune Tolerance
Integrated Nanotherapeutics (INT) is a preclinical-stage company pioneering antigen-specific immune tolerance therapies using lipid nanoparticles (LNPs).
We are developing novel immune tolerance therapies that address autoimmune diseases at their root cause.
Our Approach
Immune Tolerance Platform
Our modular immune tolerance platform enables the development of therapies to treat various autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and Allergy.
Drug Delivery Platform
Our versatile drug delivery platform allows the incorporation of virtually any small molecule and/or nucleic acid into lipid nanoparticles.
Our lead program:
INT-101 for Type 1 Diabetes
Type 1 diabetes is a lifelong autoimmune disease where the body turns against itself, destroying the cells that produce insulin. Every day is a constant balance of blood sugar monitoring, insulin injections, and uncertainty, with no cure still in sight. Current treatments manage symptoms, but they do not address the root cause. That is the gap we are determined to close.
INT-101 could change that.
Pictured is one of our scientists, Dr. Lindsay Pallo,
who has been diagnosed with T1D for 21 years.
Meet the Team
Integrated Nanotherapeutics is founded by a world-class team of scientists with multidisciplinary expertise in basic science, preclinical research, drug development, and therapeutic commercialization. Collectively, our founders and scientists bring more than 100 years of experience in lipid nanoparticle (LNP) science and drug development. Our team has contributed to five approved LNP drugs to date: Abelcet®, Myocet®, Marqibo®, Onpattro®, and Comirnaty®
Let’s begin the conversation.
We welcome partnering opportunities with academic and industry groups. INT has built a broad IP portfolio focused on LNP-based delivery of small molecules and macromolecules, including nucleic acids and peptides.
We also have a strong track record of collaborating with local and international partners to advance their preclinical assets. With deep expertise across the drug development process, from discovery through regulatory approval, we have built long-standing relationships with our partners.
Fill out the contact form or email us at bd@integratedntx.com to learn more about how our team and technologies can help you reach your drug development goals.
Thank you to our program supporters
